Phibro Animal Health Corporation (PAHC) — ESG & Values Scores

Environment story

Phibro faces significant environmental headwinds. The company has not disclosed Scope 1, 2, or 3 emissions data, and no net-zero target year is publicly stated, triggering automatic deductions. The company operates hazardous chemical manufacturing facilities with a documented history of RCRA violations, environmental fines, and consent orders. Past and ongoing contamination liabilities under CERCLA are acknowledged but unquantified. The company's core product portfolio—medically important antimicrobials (MIAs) and medicated feed additives—faces global regulatory restrictions due to antimicrobial resistance concerns, but the company has not disclosed decarbonization infrastructure investments. Voluntary removal of non-therapeutic antimicrobial claims (2017) and ongoing FDA GFI 273 compliance efforts represent regulatory adaptation rather than proactive environmental stewardship. No renewable energy percentage disclosed. Regulatory agencies are noted as showing increased scrutiny of animal health products' environmental impact.

Criticisms on file

Historical RCRA violations and environmental fines paid by subsidiaries; past consent orders for alleged environmental violations related to hazardous waste management.
Source: PAHC 10-K, Risk Factors: 'Our operations, properties and subsidiaries are subject to a wide variety of complex and stringent federal, state, local and foreign environmental laws and regulations'; 'In the past, some of our subsidiaries have paid fines and entered into consent orders to address alleged environmental violations.'
Ongoing CERCLA liability exposure for known and unknown contamination at current and former manufacturing sites, adjacent/nearby third-party sites, and offsite disposal locations.
Source: PAHC 10-K, Risk Factors: 'Given the nature of our current and former operations, particularly at our chemical manufacturing sites, we have incurred, are currently incurring and may in the future incur liabilities under CERCLA.'
FDA Notice of Opportunity for Hearing (April 2016) regarding carbadox (Mecadox) residue persistence; FDA revoked approved detection method (November 2023); company defending product in administrative hearing and D.C. Federal court lawsuit filed January 2024.
Source: PAHC 10-K, Risk Factors: 'If the FDA withdraws approval of our Mecadox (carbadox) product, the loss of sales of such product could have a material adverse effect on our business'; Mecadox sales FY2025 ~$20 million.
Regulatory agencies showing increased concern over impact of animal health products and livestock operations on the environment; increased scrutiny may require additional resources for both new and existing products.
Source: PAHC 10-K, Risk Factors: 'Furthermore, regulatory agencies are showing increasing concern over the impact of animal health products and livestock operations on the environment.'

Disclosed initiatives

FDA GFI 273 Compliance

Voluntary implementation of shorter durations of use for medically important antimicrobial products to minimize antimicrobial drug exposure and mitigate resistance development.

Regulatory alignment; may reduce product efficacy claims and sales volume but addresses systemic risk.
Voluntary Non-Therapeutic Claim Removal

Removed non-therapeutic claims from antibacterial products in 2017 in alignment with FDA GFI 209 and GFI 213 guidance.

Reduced market claims but aligns with FDA preservation objectives for human antimicrobial efficacy.

Social story

Phibro's social profile is mixed. The company maintains collective bargaining agreements covering approximately 320 Israeli and 550 Brazilian employees, indicating union presence but without evidence of active suppression or recent major strikes within 24 months. No material labor disputes or NLRB complaints are disclosed. CEO-to-median-worker pay ratio is not disclosed, preventing assessment against the 200:1 threshold. Diversity metrics for executive and board leadership are not disclosed; gender composition of workforce or technical leadership is absent from filings. The company acquired Zoetis's MFA portfolio (October 2024, $297.5M), potentially raising supply-chain complexity; no specific human-rights audits or conflict-minerals policies are disclosed. The company does not reference a formal DEI program, supplier-diversity initiative, or civil-rights audit. Supply-chain ethics for animal sourcing and medicated feed production are not addressed.

Criticisms on file

No disclosed CEO-to-median-worker pay ratio; executive compensation philosophy not detailed in available filings.
Source: PAHC 10-K SEC filing; pay equity disclosures absent from Risk Factors and MD&A sections reviewed.
No disclosed diversity metrics (gender or racial) for workforce, leadership, or board; no stated DEI program or civil-rights audit referenced.
Source: PAHC 10-K SEC filing; no Proxy Statement (DEF 14A) diversity disclosures provided in source documents.
Supply-chain human-rights policy and audits not disclosed; no conflict-minerals, forced-labor, or modern-slavery statement referenced.
Source: PAHC 10-K Risk Factors: no explicit supply-chain ethics disclosures; company operates globally with manufacturing in Israel and Brazil.

Disclosed initiatives

Collective Bargaining Agreements

Maintained labor agreements covering ~870 employees in Israel and Brazil, representing established union relationships in key manufacturing regions.

Labor stability in critical manufacturing hubs; potential ongoing cost pressure from wage negotiations.
Zoetis MFA Acquisition Integration

October 2024 acquisition of Zoetis's medically important antimicrobial (MFA) portfolio, water-soluble products, and related assets for $297.5 million; integration ongoing.

Expanded product portfolio and scale; social risks from workforce integration and customer/supplier relationship management not yet assessed.

Governance story

Phibro exhibits poor governance due to extreme concentration of voting control and reliance on controlled-company exemptions. BFI Co., LLC (Bendheim family entity) holds ~90.9% of combined voting power through dual-class structure (Class A and Class B shares with unequal voting rights), triggering a 20-point deduction for dual-class supermajority control. The company qualifies as a 'controlled company' under Nasdaq rules and explicitly elects exemptions from: (1) majority-independent board requirement, (2) independent nominating/governance committee, and (3) independent compensation committee annual evaluations. Board independence percentage is not disclosed but is inferred to be below 75% given controlled-company status. No active lobbying spend targeting environmental deregulation is disclosed, but the company faces substantial regulatory risk from FDA actions (carbadox NOOH, GFI 273 implementation). The company is not identified with active antitrust, consumer-safety, or financial-fraud proceedings, but faces ongoing product-approval defense litigation (Mecadox case, D.C. Federal court, January 2024). No shareholder proposals or climate-related governance votes are disclosed in available filings.

Criticisms on file

Extreme voting-power concentration: BFI Co., LLC holds ~90.9% of combined voting power through dual-class structure; other stockholders hold ~9.1%. Company explicitly states BFI 'will continue to be able to control all matters submitted to our stockholders for approval' including board elections and major transactions.
Source: PAHC 10-K, Risk Factors: 'Our multiple class structure and the concentration of our voting power with certain of our stockholders will limit your ability to influence corporate matters'; 'As of August 22, 2025, BFI Co., LLC...represent[s] approximately 90.9% of the combined voting power.'
Controlled company status permits exemption from majority-independent board requirement, independent nominating/governance committee, and independent compensation committee annual evaluation. Company 'utilize[s] and intend[s] to continue to utilize these exemptions.'
Source: PAHC 10-K, Risk Factors: 'We are classified as a "controlled company" and, as a result, we qualify for, and intend to rely on, exemptions from certain corporate governance requirements.'
Change-of-control provisions in debt instruments (2024 Credit Facilities) and significant contracts define change-of-control to trigger if Bendheim family voting share drops below 50% or majority of board composition changes without family/incumbent approval, creating entrenchment risk.
Source: PAHC 10-K, Risk Factors: 'We are subject to change of control provisions'; change of control defined as Bendheim family losing >50% of voting power or unapproved board majority change.
Ongoing FDA regulatory defense for carbadox (Mecadox): Notice of Opportunity for Hearing issued April 2016; FDA revoked approved residue detection method November 2023; FDA proposed withdrawal of NADA approvals; company requested full evidentiary hearing and filed D.C. Federal court lawsuit January 2024. Sales ~$20 million FY2025.
Source: PAHC 10-K, Risk Factors: 'If the FDA withdraws approval of our Mecadox (carbadox) product, the loss of sales of such product could have a material adverse effect on our business'; company 'filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox.'

Disclosed initiatives

Controlled Company Exemption Reliance

Company explicitly relies on Nasdaq Rule 5615(c) exemptions for controlled companies, waiving requirements for majority-independent board, independent nominating/governance committee, and independent compensation committee annual evaluations.

Reduces corporate governance oversight and shareholder protections; enables founder-family control without check-and-balance mechanisms standard for public companies.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Phibro Animal Health Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Phibro Animal Health Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)